Kamal Adawi - 15 Jan 2026 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
Chief Financial Officer
Signature
/s/ Cindy Tahl, as Attorney-in-Fact
Issuer symbol
FATE
Transactions as of
15 Jan 2026
Net transactions value
$0
Form type
4
Filing time
16 Jan 2026, 16:02:16 UTC
Previous filing
21 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Adawi Kamal Chief Financial Officer C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO /s/ Cindy Tahl, as Attorney-in-Fact 16 Jan 2026 0001788393

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FATE Common Stock Award $0 +25,000 +33% $0.000000 100,000 15 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (Right to Buy) Award $0 +75,000 $0.000000 75,000 15 Jan 2026 Common Stock 75,000 $1.05 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of restricted stock units ("RSUs") that vest with respect to 1/4th of the RSUs on each of January 8, 2027, January 8, 2028, January 8, 2029 and January 8, 2030, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement.
F2 The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2026, such that all of the shares shall be fully vested and exercisable on January 1, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.